Site search_Cell Therapy
BP2202
- iPSC-derived BCMA CAR-NKT cell therapy
- U.S. Phase I clinical trial for relapsed or refractory multiple myeloma
BP2202 is the Company's lead investigational allogeneic CAR-iNKT cell therapy that targets B-cell maturation antigen (BCMA), a clinically validated therapeutic target for multiple myeloma, and uses induced pluripotent stem cell (iPSC)-derived invariant natural killer T (iNKT) cells as its cellular backbone.
BP2202 is designed to combine CAR-mediated antitumor activity with native immunomodulatory functions of iNKT cells, with the goal of achieving durable clinical responses while providing a potent, readily available treatment option for patients with multiple myeloma, which remains difficult to cure.
The program was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in July 2025 for the treatment of multiple myeloma.
An open-label, multicenter, dose-escalation Phase I clinical trial in patients with relapsed or refractory multiple myeloma is currently underway in the United States.
iPSC-derived HER2 CAR-iNKT cells enhance the activity of immune cells against cancer cells
AACR 2025
Generation of functional BCMA CAR-iNKT cells from clinical-grade iPSCs via a GMP-compliant manufacturing process with capacity for linear scal-up
ASGCT 2025